Essex Woodlands Management, Inc. Long-Term Concentrated

CIK: 0001542339 · Show all filings

Period: Q3 2020 (← Previous) (Next →)

Filing Date: Nov 13, 2020

Total Value ($000): $188,207 (100.0% shares, 0.0% debt)

Holdings (8)

— REVANCE THERAPEUTICS INC 44.6%

Value ($000) $84,019 Shares 3,342,047 Est. Cost $31.50 Unrealized —

— VENUS CONCEPT, INC. 15.3%

Value ($000) $28,809 Shares 12,417,856 Est. Cost $4.17 Unrealized —

TELA TELA BIO, INC. 13.0%

Value ($000) $24,401 Shares 1,475,293 Est. Cost $12.79 Unrealized +9.8%

AXGN AXOGEN INC 12.2%

Value ($000) $23,049 Shares 1,981,888 Est. Cost $4.01 Unrealized +189.9%

— EYEPOINT PHARMACEUTICALS INC 11.6%

Value ($000) $21,793 Shares 41,909,219 Est. Cost $1.64 Unrealized —

MNOV MEDICINOVA INC 3.1%

Value ($000) $5,795 Shares 1,105,941 Est. Cost $2.95 Unrealized +95.5%

— CATALYST BIOSCIENCES INC 0.2%

Value ($000) $338 Shares 78,622 Est. Cost $7.36 Unrealized —

— ENDOLOGIX INC 0.0%

Value ($000) $3 Shares 125,747 Est. Cost $11.05 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	REVANCE THERAPEUTICS INC	3,342,047	$84,019	44.6%	$31.50	—	COM	761330109
—	VENUS CONCEPT, INC.	12,417,856	$28,809	15.3%	$4.17	—	COM	92332W105
TELA	TELA BIO, INC.	1,475,293	$24,401	13.0%	$12.79	+9.8%	COM	872381108
AXGN	AXOGEN INC	1,981,888	$23,049	12.2%	$4.01	+189.9%	COM	05463X106
—	EYEPOINT PHARMACEUTICALS INC	41,909,219	$21,793	11.6%	$1.64	—	COM	30233G100
MNOV	MEDICINOVA INC	1,105,941	$5,795	3.1%	$2.95	+95.5%	COM NEW	58468P206
—	CATALYST BIOSCIENCES INC	78,622	$338	0.2%	$7.36	—	COM NEW	14888D208
—	ENDOLOGIX INC	125,747	$3	0.0%	$11.05	—	COM NEW	29266S304